New therapy for Huntington’s disease gets £35 million boost
Drug Discovery World
OCTOBER 4, 2024
Biotechnology company LoQus23 Therapeutics has closed its £35 million (c.$43 million) Series A financing. The financing round was led by Forbion, alongside existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). Forbion General Partner Rogier Rooswinkel will join LoQus23’s Board of Directors. LoQus23 was founded in 2019 by Entrepreneurs in Residence at DDF Dr David Reynolds, Dr Caroline Benn, and Dr Ruth McKernan CBE, FMedSci and seeded by SV’s Deme
Let's personalize your content